ValuEngine downgraded shares of Alimera Sciences (NASDAQ:ALIM) from a sell rating to a strong sell rating in a research note issued to investors on Sunday.
A number of other equities research analysts have also weighed in on the stock. Zacks Investment Research upgraded shares of Alimera Sciences from a sell rating to a hold rating in a report on Friday, September 8th. HC Wainwright restated a buy rating and issued a $5.00 target price on shares of Alimera Sciences in a report on Wednesday, August 30th. Finally, Cowen restated a buy rating on shares of Alimera Sciences in a report on Thursday, November 2nd. Two equities research analysts have rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. Alimera Sciences currently has a consensus rating of Hold and a consensus target price of $3.38.
Shares of Alimera Sciences (NASDAQ:ALIM) opened at $1.29 on Friday. The company has a current ratio of 4.84, a quick ratio of 4.65 and a debt-to-equity ratio of -0.71. Alimera Sciences has a fifty-two week low of $1.06 and a fifty-two week high of $1.72.
Alimera Sciences Company Profile
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.